Karhleight (Drospirenone, Ethinylestradiol | Lactose)

The ethinylestradiol component provides estrogenic activity that stabilizes the endometrial lining, while drospirenone acts as a progestogen with anti‑mineralocorticoid and anti‑androgenic properties. Together they suppress the hypothalamic‑pituitary‑ovarian axis, inhibit the LH surge, prevent ovulation, thicken cervical mucus, and alter the endometrium to reduce the chance of implantation.

The dosing regimen for Karhleight is determined by the prescribing clinician. Typically, the product is taken once daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule, tablet strength, and any adjustments must be individualized by a qualified health professional.

Karhleight is contraindicated during pregnancy because its purpose is to prevent conception. If pregnancy occurs, the medication should be stopped immediately and medical advice sought. Use while breastfeeding is generally not recommended unless the benefits outweigh risks, and this decision should be made by a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Karhleight. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any special handling), and necessary import documentation.

Karhleight contains drospirenone, which has anti‑mineralocorticoid and anti‑androgenic activity, distinguishing it from many other progestins. This profile may offer benefits such as reduced water retention and potential improvement in acne, while maintaining contraceptive efficacy comparable to other estrogen‑progestogen pills. Choice of product should be based on individual risk factors and physician assessment.

Karhleight tablets should be stored at room temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Karhleight is taken orally, usually one tablet at the same time each day. The standard regimen consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their prescriber and read the patient information leaflet.

The most serious potential risks include venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, and severe liver disease. These events are more likely in women who smoke, have a history of clotting disorders, or possess other cardiovascular risk factors. Immediate medical attention is required if symptoms such as leg pain, chest pain, or severe headache develop.

Karhleight is contraindicated in women with a known or suspected pregnancy, active or past thromboembolic disease, uncontrolled hypertension, certain liver tumors, or known hypersensitivity to drospirenone, ethinylestradiol, or any tablet excipients. It should also be avoided in smokers over 35 years of age and in individuals with estrogen‑dependent malignancies unless specifically directed by a physician.